卡博赞替尼联合尼武单抗治疗转移性肾细胞癌患者的病理完全缓解案例系列与文献回顾

IF 2.7 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-03-07 DOI:10.1016/j.clgc.2025.102328

Marco Stellato MD , Simone Rota MD , Melanie Claps MD , Valentina Guadalupi MD , Alessandro Rametta MD , Giuseppe Fotia MD , Marco Barella MD , Elena Verzoni MD , Giuseppe Procopio MD

{"title":"卡博赞替尼联合尼武单抗治疗转移性肾细胞癌患者的病理完全缓解案例系列与文献回顾","authors":"Marco Stellato MD , Simone Rota MD , Melanie Claps MD , Valentina Guadalupi MD , Alessandro Rametta MD , Giuseppe Fotia MD , Marco Barella MD , Elena Verzoni MD , Giuseppe Procopio MD","doi":"10.1016/j.clgc.2025.102328","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Cabozantinib plus nivolumab could be safe and effective in metastatic Renal Cell Carcinoma patients with oligometastatic disease and primary in site.</div></span></li><li><span>•</span><span><div>IO-TKI is associated to high response rate that sometimes includes pathological Complete Response.</div></span></li><li><span>•</span><span><div>Cytoreductive Nephrectomy should be considered in multidisciplinary team as an option for selected patients with low disease burden, fit for surgery, especially following a favorable response to systemic treatment.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102328"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review\",\"authors\":\"Marco Stellato MD , Simone Rota MD , Melanie Claps MD , Valentina Guadalupi MD , Alessandro Rametta MD , Giuseppe Fotia MD , Marco Barella MD , Elena Verzoni MD , Giuseppe Procopio MD\",\"doi\":\"10.1016/j.clgc.2025.102328\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div>Cabozantinib plus nivolumab could be safe and effective in metastatic Renal Cell Carcinoma patients with oligometastatic disease and primary in site.</div></span></li><li><span>•</span><span><div>IO-TKI is associated to high response rate that sometimes includes pathological Complete Response.</div></span></li><li><span>•</span><span><div>Cytoreductive Nephrectomy should be considered in multidisciplinary team as an option for selected patients with low disease burden, fit for surgery, especially following a favorable response to systemic treatment.</div></span></li></ul></div></div>\",\"PeriodicalId\":10380,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":\"23 3\",\"pages\":\"Article 102328\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767325000291\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000291","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

•Cabozantinib + nivolumab对于转移性肾细胞癌低转移性和原发部位患者是安全有效的。•IO-TKI与高缓解率相关，有时包括病理完全缓解。•对于疾病负担低、适合手术的患者，特别是在对全身治疗有良好反应的情况下，应在多学科团队中考虑采用减量肾切除术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review

•
Cabozantinib plus nivolumab could be safe and effective in metastatic Renal Cell Carcinoma patients with oligometastatic disease and primary in site.
•
IO-TKI is associated to high response rate that sometimes includes pathological Complete Response.
•
Cytoreductive Nephrectomy should be considered in multidisciplinary team as an option for selected patients with low disease burden, fit for surgery, especially following a favorable response to systemic treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.